SlideShare a Scribd company logo
1 of 15
IN VIVO MODEL OF
DEPRESSION
Umangi Chauhan
NIPERA1214PC05
1
DEPRESSION
 Depression is defined as disorders of mood rather than
disturbances of thought or cognition; it may range from a
very mild condition, bordering on normality, to severe
(psychotic) depression accompanied by hallucinations and
delusions.
 Worldwide, depression is a major cause of disability and
premature death.
2
SYMPTOMS
 Emotional symptoms:
 misery, apathy and pessimism
 low self-esteem: feelings of guilt, inadequacy and ugliness
 indecisiveness, loss of motivation
 Biological symptoms:
 retardation of thought and action
 loss of libido
 sleep disturbance and loss of appetite
TYPES
o Unipolar depression
o Bipolar depression 3
THEORIES OF DEPRESSION
1. Monoamine theory:
• Monoamine hypothesis, proposed by Schildkraut in 1965,
which states that depression is caused by a functional
deficit of monoamine transmitters at certain sites in the
brain, while mania results from a functional excess i.e.
NA,5-HT.
2. Neuroendocrine mechanism:
• Increase cortisol, growth hormone concentration is
reduced and prolactin is increased.
• But these changes are nonspecific.
3. Neuroplasticity:
• Depression is associated with neuronal loss in the
hippocampus and prefrontal cortex.
• Antidepressant therapies of different kinds act by
inhibiting or actually reversing this loss by stimulating
neurogenesis.
4
ANIMAL MODELS OF DEPRESSION
 Despair swim test
 Tail suspension test in mice
 Learned helplessness in rats
 Muricide behaviour in rats
 Potentiation of norepinephrine toxicity
 Reserpine induced hypothermia
5
DESPAIR SWIM TEST
 Mice or rats forced to swim in a restricted space from which they
cannot escape are induced to a characteristic behavior of
immobility.
 Method:
 Rats placed in the cylinders for the first time
 Initially-They are highly active
 After 2-3 min-Starting of immobility or floating
 After 5-6 min-Remain immobile
 Test drugs or standard are administered one hour prior to
testing.
 Evaluation
 Duration of immobility is measured in controls and animals
treated with various doses of a test drug or standard.
6
TAIL SUSPENSION TEST IN MICE
 The immobility displayed by rodents when subjected to an
unavoidable and inescapable stress has been reflect
depressive disorders in humans.
 Method
 Male Balb/cJ mice weighing 20–25 g are used
 Animals are treated with the test compounds or the
vehicle by i.p. injection 30 min prior to testing.
 Mice are suspended on the edge of a shelf 58 cm above a
table top by adhesive tape placed approximately 1 cm
from the tip of the tail.
 The duration of immobility is recorded for a period of 5
min.
7
 Evaluation
 The percentage of animals showing the passive behavior is
counted and compared with vehicle treated controls.
 Using various doses, ED50 values can be calculated.
8
LEARNED HELPLESSNESS IN RATS
 Animals exposed to inescapable and unavoidable electric
shocks in one situation later fail to escape shock in a
different situation when escape is possible
 Method
 Learned helplessness is produced in male Sprague-
Dawley rats (300 g) by exposure to electric shock (0.7 mA)
for 1 h on a schedule of 10 s of shock/min.
 The platform is not available during training.
 After giving test drug,the shock is initiated (0.4 mA)
 Shock is terminated in 10 s if the animal has not escaped
onto the platform by this time.
9
 If an escape response occurred, the animal is allowed to
remain on the platform for the duration of 10 s, then
returned to the grid floor.
 Ten such trials with an interval of 20 s are given.
 Evaluation
 A drug is considered to be effective, if the learned
helplessness is reduced and the number of failures to
escape is decreased.
10
MURICIDE BEHAVIOUR IN RATS
 A selective inhibition of mouse-killing behavior in rats by
antidepressants.
 Method
 Male SD rats (300–350 g) are isolated for 6 weeks in
individual cages.
 One mouse is placed into the rat’s cage. About 10 to 30% of
rats kill the mouse by biting the animal through the cervical
cord.
 Only rats consistently killing mice within 5 min after
presentation are used for the test.
 Drugs are injected i.p. to the rats before the test.
 Mice are presented 30, 60 and 120 min after drug
administration. 11
 Evaluation
 Failure to kill a mouse within 5 min is considered inhibition
of muricidal behavior.
 The ED50 is calculated(dose which inhibits mouse killing
in 50% of the rats.)
 Modifications
 Injections of 5,7-dihydroxytryptamine into the lateral
hypothalamus increased mouse-killing behavior in rats
12
POTENTIATION OF NOREPINEPHRINE TOXICITY
 Antidepressants block the re-uptake of biogenic amines into
nervous tissue. In this way, the toxic effects of
norepinephrine are potentiated.
 Method
 Male NMRI mice (22–25 g) are randomly assigned to test
groups of 10 subjects.
 The test drug, the standard or the vehicle are given orally 1
h prior to the s.c. injection of the sublethal dose of 3 mg/kg
noradrenaline.
 Evaluation
 The mortality rate is assessed 48 h post-dosing. ED50,or
dose which causes death of 50% of the treated subjects,is
calculated
13
RESERPINE INDUCED HYPOTHERMIA
 Depletion of biogenic amines (noradrenaline, 5-
hydroxytryptamine, dopamine) in the brain induces not
only catalepsy and ptosis but also hypothermia in rodents.
 The decrease of body temperature induced by reserpine is
antagonized by antidepressants, MAO-inhibitors and
central stimulants.
 Method
 Groups of male NMRI mice (19–21 g body weight)are
used
 On the day before testing, they are dosed with 2 mg/kg
reserpine s.c.
14
 Eighteen hours after reserpine administration, the animals
are placed into individual cages.
 The initial rectal temperature is determined by insertion of
an electronic thermometer
 Following administration of the test compound (either i.p.
or p.o.), the rectal temperature is measured again at 60
min intervals for 7 h.
 Evaluation
 Rectal temperature is recorded every hour.
 The difference in temperature from vehicle controls is
calculated for each time and the maximal difference is
scored.
15

More Related Content

What's hot

Screening of antihypertensive agents
Screening of antihypertensive agentsScreening of antihypertensive agents
Screening of antihypertensive agents
Kanthlal SK
 
Antipsychotic screening- Dr Divya Krishnan
Antipsychotic screening- Dr Divya Krishnan Antipsychotic screening- Dr Divya Krishnan
Antipsychotic screening- Dr Divya Krishnan
Divya Krishnan
 

What's hot (20)

Screening method of nootropics vikas malik
Screening method of nootropics vikas malikScreening method of nootropics vikas malik
Screening method of nootropics vikas malik
 
Screening models of alzheimer disease
Screening models of alzheimer diseaseScreening models of alzheimer disease
Screening models of alzheimer disease
 
Pharmacological screening of Anti-psychotic agents
Pharmacological screening of Anti-psychotic agentsPharmacological screening of Anti-psychotic agents
Pharmacological screening of Anti-psychotic agents
 
Screening of Anti depressant
Screening of Anti depressantScreening of Anti depressant
Screening of Anti depressant
 
Screening of antihypertensive agents
Screening of antihypertensive agentsScreening of antihypertensive agents
Screening of antihypertensive agents
 
Screening of antiparkinsonian agents
Screening of antiparkinsonian agentsScreening of antiparkinsonian agents
Screening of antiparkinsonian agents
 
SCREENING MODELS OF ANTIDYSLIPIDEMIC AGENT.docx
SCREENING MODELS OF ANTIDYSLIPIDEMIC AGENT.docxSCREENING MODELS OF ANTIDYSLIPIDEMIC AGENT.docx
SCREENING MODELS OF ANTIDYSLIPIDEMIC AGENT.docx
 
Preclinical screening methods of cns stimulants
Preclinical screening methods of cns stimulantsPreclinical screening methods of cns stimulants
Preclinical screening methods of cns stimulants
 
Screening models of antiepileptic and nootropic drugs
Screening models of antiepileptic and nootropic drugsScreening models of antiepileptic and nootropic drugs
Screening models of antiepileptic and nootropic drugs
 
Screening Methods of Parkinson's Disease
Screening Methods of Parkinson's DiseaseScreening Methods of Parkinson's Disease
Screening Methods of Parkinson's Disease
 
Screening Methods for behavioural and muscle Coordination
 Screening Methods for behavioural and muscle Coordination Screening Methods for behavioural and muscle Coordination
Screening Methods for behavioural and muscle Coordination
 
Screening methods of anxiolytics
Screening methods of anxiolyticsScreening methods of anxiolytics
Screening methods of anxiolytics
 
Antipsychotic screening- Dr Divya Krishnan
Antipsychotic screening- Dr Divya Krishnan Antipsychotic screening- Dr Divya Krishnan
Antipsychotic screening- Dr Divya Krishnan
 
Multiple sclerosis screening methods
Multiple sclerosis screening methodsMultiple sclerosis screening methods
Multiple sclerosis screening methods
 
Pre clinical screening models for drugs acting on Autonomic nervous system
Pre clinical screening models for drugs acting on Autonomic nervous systemPre clinical screening models for drugs acting on Autonomic nervous system
Pre clinical screening models for drugs acting on Autonomic nervous system
 
Screening of anti alzheimers
Screening of anti alzheimersScreening of anti alzheimers
Screening of anti alzheimers
 
Screening models of Anti diabetics.
Screening models of Anti diabetics.Screening models of Anti diabetics.
Screening models of Anti diabetics.
 
Anti epileptic screening model
Anti epileptic screening modelAnti epileptic screening model
Anti epileptic screening model
 
Preclinical Screening of Antipsychotic Agents
Preclinical Screening of Antipsychotic Agents Preclinical Screening of Antipsychotic Agents
Preclinical Screening of Antipsychotic Agents
 
screening model for Multiple sclerosis
 screening model for Multiple sclerosis screening model for Multiple sclerosis
screening model for Multiple sclerosis
 

Viewers also liked

Screening of anti anxiety drugs
Screening of anti anxiety drugsScreening of anti anxiety drugs
Screening of anti anxiety drugs
Bindu Pulugurtha
 
screening of anxiolytics
screening of anxiolyticsscreening of anxiolytics
screening of anxiolytics
Sayanti Sau
 

Viewers also liked (20)

Neuropharmacology: Methods
Neuropharmacology: MethodsNeuropharmacology: Methods
Neuropharmacology: Methods
 
Screening of anti anxiety drugs
Screening of anti anxiety drugsScreening of anti anxiety drugs
Screening of anti anxiety drugs
 
Learned helplessness &_control
Learned helplessness &_controlLearned helplessness &_control
Learned helplessness &_control
 
Antidepressant drugs
Antidepressant drugsAntidepressant drugs
Antidepressant drugs
 
Neuropharmacology: Introduction
Neuropharmacology: IntroductionNeuropharmacology: Introduction
Neuropharmacology: Introduction
 
Introduction to Central Nervous system Pharmacology : Dr Rahul Kunkulol's Pow...
Introduction to Central Nervous system Pharmacology : Dr Rahul Kunkulol's Pow...Introduction to Central Nervous system Pharmacology : Dr Rahul Kunkulol's Pow...
Introduction to Central Nervous system Pharmacology : Dr Rahul Kunkulol's Pow...
 
Self esteem and depression
Self esteem and depressionSelf esteem and depression
Self esteem and depression
 
Optogenetics a light switch for brain
Optogenetics a light switch for brainOptogenetics a light switch for brain
Optogenetics a light switch for brain
 
screening of anxiolytics
screening of anxiolyticsscreening of anxiolytics
screening of anxiolytics
 
Electrophysiology meets Optogenetics
Electrophysiology meets Optogenetics  Electrophysiology meets Optogenetics
Electrophysiology meets Optogenetics
 
Learned Helplessness
Learned HelplessnessLearned Helplessness
Learned Helplessness
 
NEUROPHAMACOLOGY
NEUROPHAMACOLOGYNEUROPHAMACOLOGY
NEUROPHAMACOLOGY
 
Hypertension
HypertensionHypertension
Hypertension
 
Selective serotonin reuptake inhibitors 2016
Selective serotonin reuptake inhibitors 2016Selective serotonin reuptake inhibitors 2016
Selective serotonin reuptake inhibitors 2016
 
Screening of anti obesity drugs
Screening of anti obesity drugs Screening of anti obesity drugs
Screening of anti obesity drugs
 
Experimental evaluation of anti inflammatory agents
Experimental evaluation of anti inflammatory agentsExperimental evaluation of anti inflammatory agents
Experimental evaluation of anti inflammatory agents
 
Screening of Anxiolytics
Screening of AnxiolyticsScreening of Anxiolytics
Screening of Anxiolytics
 
Introduction to Neuropharmacology
Introduction to Neuropharmacology Introduction to Neuropharmacology
Introduction to Neuropharmacology
 
Screening models for inflammatory drugs
Screening models for inflammatory drugsScreening models for inflammatory drugs
Screening models for inflammatory drugs
 
Preclinical screening methods of Sedative and hypnotics by syed
Preclinical screening methods of Sedative and hypnotics by syedPreclinical screening methods of Sedative and hypnotics by syed
Preclinical screening methods of Sedative and hypnotics by syed
 

Similar to In vivo model of depression

Similar to In vivo model of depression (20)

Screening of anti psychotic drugs salim
Screening of anti psychotic drugs  salimScreening of anti psychotic drugs  salim
Screening of anti psychotic drugs salim
 
Anxiolytic poonam ppt.pptx
Anxiolytic poonam ppt.pptxAnxiolytic poonam ppt.pptx
Anxiolytic poonam ppt.pptx
 
Screening Methods of Anti-epileptic drugs
Screening Methods of Anti-epileptic drugsScreening Methods of Anti-epileptic drugs
Screening Methods of Anti-epileptic drugs
 
Analgesics.pptx
Analgesics.pptxAnalgesics.pptx
Analgesics.pptx
 
Evaluation of antidepressants.pptx
Evaluation of antidepressants.pptxEvaluation of antidepressants.pptx
Evaluation of antidepressants.pptx
 
Antipsychotic screening models
Antipsychotic screening modelsAntipsychotic screening models
Antipsychotic screening models
 
Screening Models for Parkinson's Disease ppt
Screening Models  for Parkinson's Disease pptScreening Models  for Parkinson's Disease ppt
Screening Models for Parkinson's Disease ppt
 
Analgesic screening methods
Analgesic screening methodsAnalgesic screening methods
Analgesic screening methods
 
Determination of anticonvulsant activity of drugs using animal models
Determination of anticonvulsant activity of drugs using animal modelsDetermination of anticonvulsant activity of drugs using animal models
Determination of anticonvulsant activity of drugs using animal models
 
Pharmacological screening of analgesic activity
Pharmacological screening of analgesic activityPharmacological screening of analgesic activity
Pharmacological screening of analgesic activity
 
Anti psychotic screening methods
Anti psychotic screening methodsAnti psychotic screening methods
Anti psychotic screening methods
 
Antidepressant
AntidepressantAntidepressant
Antidepressant
 
Epilesy
EpilesyEpilesy
Epilesy
 
Screening of depressents by Kashikant Yadav
Screening of depressents  by Kashikant YadavScreening of depressents  by Kashikant Yadav
Screening of depressents by Kashikant Yadav
 
Anxiolytics screening methods
Anxiolytics screening methodsAnxiolytics screening methods
Anxiolytics screening methods
 
Pre clinical screening of anti epileptic drugs
Pre clinical screening of anti epileptic drugsPre clinical screening of anti epileptic drugs
Pre clinical screening of anti epileptic drugs
 
Cns stimulants and depressants screening models
Cns stimulants and depressants screening modelsCns stimulants and depressants screening models
Cns stimulants and depressants screening models
 
Screening of centrally acting muscle relaxant agents
Screening of centrally acting muscle relaxant agentsScreening of centrally acting muscle relaxant agents
Screening of centrally acting muscle relaxant agents
 
M pharm 1
M pharm 1M pharm 1
M pharm 1
 
Muscle relaxants by ved prakash
Muscle relaxants by ved prakashMuscle relaxants by ved prakash
Muscle relaxants by ved prakash
 

In vivo model of depression

  • 1. IN VIVO MODEL OF DEPRESSION Umangi Chauhan NIPERA1214PC05 1
  • 2. DEPRESSION  Depression is defined as disorders of mood rather than disturbances of thought or cognition; it may range from a very mild condition, bordering on normality, to severe (psychotic) depression accompanied by hallucinations and delusions.  Worldwide, depression is a major cause of disability and premature death. 2
  • 3. SYMPTOMS  Emotional symptoms:  misery, apathy and pessimism  low self-esteem: feelings of guilt, inadequacy and ugliness  indecisiveness, loss of motivation  Biological symptoms:  retardation of thought and action  loss of libido  sleep disturbance and loss of appetite TYPES o Unipolar depression o Bipolar depression 3
  • 4. THEORIES OF DEPRESSION 1. Monoamine theory: • Monoamine hypothesis, proposed by Schildkraut in 1965, which states that depression is caused by a functional deficit of monoamine transmitters at certain sites in the brain, while mania results from a functional excess i.e. NA,5-HT. 2. Neuroendocrine mechanism: • Increase cortisol, growth hormone concentration is reduced and prolactin is increased. • But these changes are nonspecific. 3. Neuroplasticity: • Depression is associated with neuronal loss in the hippocampus and prefrontal cortex. • Antidepressant therapies of different kinds act by inhibiting or actually reversing this loss by stimulating neurogenesis. 4
  • 5. ANIMAL MODELS OF DEPRESSION  Despair swim test  Tail suspension test in mice  Learned helplessness in rats  Muricide behaviour in rats  Potentiation of norepinephrine toxicity  Reserpine induced hypothermia 5
  • 6. DESPAIR SWIM TEST  Mice or rats forced to swim in a restricted space from which they cannot escape are induced to a characteristic behavior of immobility.  Method:  Rats placed in the cylinders for the first time  Initially-They are highly active  After 2-3 min-Starting of immobility or floating  After 5-6 min-Remain immobile  Test drugs or standard are administered one hour prior to testing.  Evaluation  Duration of immobility is measured in controls and animals treated with various doses of a test drug or standard. 6
  • 7. TAIL SUSPENSION TEST IN MICE  The immobility displayed by rodents when subjected to an unavoidable and inescapable stress has been reflect depressive disorders in humans.  Method  Male Balb/cJ mice weighing 20–25 g are used  Animals are treated with the test compounds or the vehicle by i.p. injection 30 min prior to testing.  Mice are suspended on the edge of a shelf 58 cm above a table top by adhesive tape placed approximately 1 cm from the tip of the tail.  The duration of immobility is recorded for a period of 5 min. 7
  • 8.  Evaluation  The percentage of animals showing the passive behavior is counted and compared with vehicle treated controls.  Using various doses, ED50 values can be calculated. 8
  • 9. LEARNED HELPLESSNESS IN RATS  Animals exposed to inescapable and unavoidable electric shocks in one situation later fail to escape shock in a different situation when escape is possible  Method  Learned helplessness is produced in male Sprague- Dawley rats (300 g) by exposure to electric shock (0.7 mA) for 1 h on a schedule of 10 s of shock/min.  The platform is not available during training.  After giving test drug,the shock is initiated (0.4 mA)  Shock is terminated in 10 s if the animal has not escaped onto the platform by this time. 9
  • 10.  If an escape response occurred, the animal is allowed to remain on the platform for the duration of 10 s, then returned to the grid floor.  Ten such trials with an interval of 20 s are given.  Evaluation  A drug is considered to be effective, if the learned helplessness is reduced and the number of failures to escape is decreased. 10
  • 11. MURICIDE BEHAVIOUR IN RATS  A selective inhibition of mouse-killing behavior in rats by antidepressants.  Method  Male SD rats (300–350 g) are isolated for 6 weeks in individual cages.  One mouse is placed into the rat’s cage. About 10 to 30% of rats kill the mouse by biting the animal through the cervical cord.  Only rats consistently killing mice within 5 min after presentation are used for the test.  Drugs are injected i.p. to the rats before the test.  Mice are presented 30, 60 and 120 min after drug administration. 11
  • 12.  Evaluation  Failure to kill a mouse within 5 min is considered inhibition of muricidal behavior.  The ED50 is calculated(dose which inhibits mouse killing in 50% of the rats.)  Modifications  Injections of 5,7-dihydroxytryptamine into the lateral hypothalamus increased mouse-killing behavior in rats 12
  • 13. POTENTIATION OF NOREPINEPHRINE TOXICITY  Antidepressants block the re-uptake of biogenic amines into nervous tissue. In this way, the toxic effects of norepinephrine are potentiated.  Method  Male NMRI mice (22–25 g) are randomly assigned to test groups of 10 subjects.  The test drug, the standard or the vehicle are given orally 1 h prior to the s.c. injection of the sublethal dose of 3 mg/kg noradrenaline.  Evaluation  The mortality rate is assessed 48 h post-dosing. ED50,or dose which causes death of 50% of the treated subjects,is calculated 13
  • 14. RESERPINE INDUCED HYPOTHERMIA  Depletion of biogenic amines (noradrenaline, 5- hydroxytryptamine, dopamine) in the brain induces not only catalepsy and ptosis but also hypothermia in rodents.  The decrease of body temperature induced by reserpine is antagonized by antidepressants, MAO-inhibitors and central stimulants.  Method  Groups of male NMRI mice (19–21 g body weight)are used  On the day before testing, they are dosed with 2 mg/kg reserpine s.c. 14
  • 15.  Eighteen hours after reserpine administration, the animals are placed into individual cages.  The initial rectal temperature is determined by insertion of an electronic thermometer  Following administration of the test compound (either i.p. or p.o.), the rectal temperature is measured again at 60 min intervals for 7 h.  Evaluation  Rectal temperature is recorded every hour.  The difference in temperature from vehicle controls is calculated for each time and the maximal difference is scored. 15